Involvement of dorsolateral periaqueductal gray N-methyl-D-aspartic acid glutamate receptors in the regulation of risk assessment and inhibitory avoidance behaviors in the rat elevated T-maze

Behavioural Pharmacology

Volumn 17, Issue 7, 2006, Pages 589-596

  Bertoglio, Leandro José ^a   Zangrossi Jr , Hélio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anxiety; Dorsolateral periaqueductal gray; Elevated T maze; Glutamate; N methyl D aspartic acid receptors; Rat

Indexed keywords

2 AMINO 7 PHOSPHONOHEPTANOIC ACID; ANXIOLYTIC AGENT; BENZODIAZEPINE; ETHOSUXIMIDE; FLUNIXIN MEGLUMINE; FLUOXETINE; GLUTAMATE RECEPTOR; IMIPRAMINE; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PENICILLIN G; STREPTOMYCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DEFENSIVE BEHAVIOR; ESCAPE BEHAVIOR; EXPLORATORY BEHAVIOR; MALE; MAZE TEST; MESENCEPHALON; NONHUMAN; OPEN FIELD BEHAVIOR; PERIAQUEDUCTAL GRAY MATTER; RAT; RISK ASSESSMENT;

2-AMINO-5-PHOSPHONOVALERATE; ANIMALS; ANTICONVULSANTS; ANXIETY; ETHOSUXIMIDE; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; FEAR; HIPPOCAMPUS; MALE; MICROINJECTIONS; N-METHYLASPARTATE; PERIAQUEDUCTAL GRAY; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; RISK-TAKING;

EID: 33749505835     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fbp.0000236270.64676.b4     Document Type: Article

References (51)

1. Albin RL, Makowiec RL, Hollingsworth Z, Dure LS, Penney JB, Young AB (1990). Excitatory amino acid binding sites in the periaqueductal gray of the rat. Neurosci Lett 118:112-115.
2. Amano K, Tanikawa T, Iseki H, Kawabatabe H, Notani M, Kawamura H, Kitamura K (1978). Single neuron analysis of the human midbrain tegmentum. Rostral mesencephalic reticulotomy for pain relief. Appl Neurophysiol 41:66-78.
3. Argyropoulos SV, Sandford JJ, Nutt DJ (2000). The psychobiology of anxiolytic drug. Part 2: pharmacological treatments of anxiety. Pharmacol Ther 88:213-227.
4. Bandler R, Depaulis A (1991). Midbrain periaqueductal gray control of defensive behavior in the cat and the rat. In: Depaulis A, Bandler R, editors. The midbrain periaqueductal gray matter. New York: Plenum Press. pp. 175-198.
5. Bandler R, Shipley MT (1994). Columnar organization in the midbrain periaqueductal gray: modules for emotional expression? Trends Neurosci 17:379-389.
6. Beckett SR, Lawrence AJ, Marsden CA, Marshall PW (1992). Attenuation of chemically induced defence response by 5-HT1 receptor agonists administered into the periaqueductal gray. Psychopharmacology 108:110-114.
7. Behbehani MM (1995). Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol 46:575-605.
8. Beitz AJ, Williams FG (1991). Localization of putative amino acid transmitters in the PAG and their relationship to PAG-raphe magnus pathway. In: Depaulis A, Bandler R, editors. The midbrain periaqueductal gray matter: functional, anatomical and neurochemical organization. New York: Plenum Press. pp. 305-327.
9. Bertoglio LJ, Zangrossi H Jr (2005). Involvement of dorsolateral periaqueductal gray cholecystokinin-2 receptors in the regulation of a panic-related behavior in rats. Brain Res 1059:46-51.
10. Bertoglio LJ, Anzini C, Lino-de-Oliveira C, Carobrez AP (2005). Enhanced dorsolateral periaqueductal gray activity counteracts the anxiolytic response to midazolam on the elevated plus-maze trial 2 in rats. Behav Brain Res 162:99-107.
11. Bittencourt AS, Carobrez AP, Zamprogno LP, Tufik S, Schenberg LC (2004). Organization of single components of defensive behaviors within distinct columns of periaqueductal gray matter of the rat: role of N-methyl-D-aspartic acid glutamate receptors. Neuroscience 125:71-89.
12. Blanchard DC, Griebel G, Blanchard RJ (2001). Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic. Neurosci Biobehav Rev 25:205-218.
13. Blanchard DC, Griebel G, Blanchard RJ (2003). The mouse defense test battery: pharmacological and behavioral assays for anxiety and panic. Eur J Pharmacol 463:97-116.
14. Bourin M, Dailly E (2004). Cholecystokinin and panic disorder. Acta Neuropsychiatr 16:85-93.
15. Carobrez AP, Bertoglio LJ (2005). Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neurosci Biobehav Rev 29:1193-1205.
16. Carobrez AP, Teixeira KV, Graeff FG (2001). Modulation of defensive behavior by periaqueductal gray NMDA/glycine-B receptor. Neurosci Biobehav Rev 25:697-709.
17. De Bortoli VC, Nogueira RL, Zangrossi H Jr (2006). Effects of fluoxetine and buspirone on the panicolytic-like response induced by the activation of 5-HT1A and 5-HT2A receptors in the rat dorsal periaqueductal gray. Psychopharmacology 183:422-428.
18. De Oliveira RM, Del Bel EA, Guimaraes FS (2001). Effects of excitatory amino acids and nitric oxide on flight behavior elicited from the dorsolateral periaqueductal gray. Neurosci Biobehav Rev 25:679-685.
19. De-Souza MM, Schenberg LC, Carobrez AP (1998). NMDA-coupled periaqueductal gray glycine receptors modulate anxioselective drug effects on plus-maze performance. Behav Brain Res 90:157-165.
20. Ferreira-Netto C, Borelli KG, Brandao ML (2005). Neural segregation of Fos-protein distribution in the brain following freezing and escape behaviors induced by injections of either glutamate or NMDA into the dorsal periaqueductal gray of rats. Brain Res 1031:151-163.
21. Graeff FG (1994). Neuroanatomy and neurotransmitter regulation of defensive behaviors and related emotions in mammals. Braz J Med Biol Res 27:811-829.
22. Graeff FG (2002). On serotonin and experimental anxiety. Psychopharmacology 163:467-476.
23. Graeff FG, Zangrossi H Jr (2002). Animal models of anxiety disorders. In: D'Haenen H, den Boer JA, Willner P, editors. Biological psychiatry. Chichester: Wiley. pp. 879-893.
24. Graeff FG, Netto CF, Zangrossi H Jr (1998). The elevated T-maze as an experimental model of anxiety. Neurosci Biobehav Res 23:237-246.
25. Gray AJ, McNaughton N, editors (2000). The neuropsychology of anxiety. 2nd ed. New York: Oxford University Press.
26. Guimaraes FS, Carobrez AP, De Aguiar JC, Graeff FG (1991). Anxiolytic effect in the elevated plus-maze of the NMDA receptor antagonist AP7 microinjected into the dorsal periaqueductal grey. Psychopharmacology 103:91-94.
27. Guimaraes FS, Russo AS, De Aguiar JC, Ballejo G, Graeff FG (1992). Anxiogenic-like effect of CCK-8 micro-injected into the dorsal periaqueductal grey of rats in the elevated plus maze In: Dourish CT, Cooper SJ, Iversen SD, Iversen LL, editors. Multiple cholecystokinin receptors in the CNS. Oxford: Oxford Science Publication. pp. 149-154.
28. Gundlach AL (1991). Regional subdivisions in the midbrain periaqueductal gray of the cat revealed by in vitro receptor autoradiography. In: Depaulis A, Bandler R, editors. The midbrain periaqueductal gray matter: functional, anatomical and neurochemical organization. New York: Plenum Press. pp. 449-464.
29. Handley SL, McBlane JW (1993). An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J Pharmacol Toxicol Methods 29:129-138.
30. Krieger JE, Graeff FG (1985). Defensive behavior and hypertension induced by glutamate in the midbrain central gray of the rat. Braz J Med Biol Res 18:61-67.
31. Jenck F, Moreau JL, Martin JR (1995). Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiatry Res 57:181-191.
32. Lovick TA (2000). Panic disorder: a malfunction of multiple transmitter control systems within the midbrain periaqueductal gray matter? Neuroscientist 6:48-59.
33. Matheus MG, Nogueira RL, Carobrez AP, Graeff FG, Guimaraes FS (1994). Anxiolytic effect of glycine antagonists microinjected into the dorsal periaqueductal grey. Psychopharmacology 113:565-569.
34. Nashold BS Jr, Wilson WP, Slaughter DG (1969). Sensations evoked by stimulation in the midbrain of man. J Neurosurg 30:14-24.
35. Netto CF, Guimaraes FS (2004). Anxiogenic effect of cholecystokinin in the dorsal periaqueductal gray. Neuropsychopharmacology 29:101-107.
36. Olds ME, Olds J (1962). Approach-escape interactions in rat brain. Am J Physiol 203:803-810.
37. Paxinos G, Watson C, editors (1998). The rat brain in stereotaxic coordinates. 4th ed. San Diego: Academic Press.
38. Pellow S, Chopin P, File SE, Briley M (1985). Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149-167.
39. Poltronieri SC, Zangrossi H Jr, de Barros Viana M (2003). Antipanic-like effect of serotonin reuptake inhibitors in the elevated T-maze. Behav Brain Res 147:185-192.
40. Rodgers RJ, Cole JC (1994). The elevated plus-maze: pharmacology, methodology and ethology. In: Cooper SJ, Hendrie CA, editors. Ethology and psychopharmacology. Chichester: Wiley. pp. 9-44.
41. Russo AS, Guimaraes FS, De Aguiar JC, Graeff FG (1993). Role of benzodiazepine receptors located in the dorsal periaqueductal grey of rats in anxiety. Psychopharmacology 110:198-202.
42. Schenberg LC, Bittencourt AS, Sudre EC, Vargas LC (2001). Modeling panic attacks. Neurosci Biobehav Rev 25:647-659.
43. Schmitt ML, Coelho W, Lopes-de-Souza AS, Guimaraes FS, Carobrez AP (1995). Anxiogenic-like effect of glycine and D-serine microinjected into dorsal periaqueductal gray matter of rats. Neurosci Lett 189:93-96.
44. Schutz MT, de Aguiar JC, Graeff FG (1985). Anti-aversive role of serotonin in the dorsal periaqueductal grey matter. Psychopharmacology 85:340-345.
45. Teixeira KV, Carobrez AP (1999). Effects of glycine or ( ± )-3-amino-1-hydroxy-2-pyrrolidone microinjections along the rostrocaudal axis of the dorsal periaqueductal gray matter on rats' performance in the elevated plus-maze task. Behav Neurosci 113:196-203.
46. Teixeira RC, Zangrossi H, Graeff FG (2000). Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety. Pharmacol Biochem Behav 65:571-576.
47. Vianna DM, Brandao ML (2003). Anatomical connections of the periaqueductal gray: specific neural substrates for different kinds of fear. Braz J Med Biol Res 36:557-566.
48. Vianna DM, Graeff FG, Landeira-Fernandez J, Brandao ML (2001a). Lesion of the ventral periaqueductal gray reduces conditioned fear but does not change freezing induced by stimulation of the dorsal periaqueductal gray. Learn Mem 8:164-169.
49. Vianna DM, Landeira-Fernandez J, Brandao ML (2001b). Dorsolateral and ventral regions of the periaqueductal gray matter are involved in distinct types of fear. Neurosci Biobehav Rev 25:711-719.
50. Zangrossi H Jr, Viana MB, Zanoveli J, Bueno C, Nogueira RL, Graeff FG (2001). Serotonergic regulation of inhibitory avoidance and one-way escape in the rat elevated T-maze. Neurosci Biobehav Rev 25:637-645.
51. Zanoveli JM, Netto CF, Guimaraes FS, Zangrossi H Jr (2004). Systemic and intradorsal periaqueductal gray injections of cholecystokinin sulfated octapeptide (CCK-8s) induce a panic-like response in rats submitted to the elevated T-maze. Peptides 25:1935-1941.